Fol. Biol. 2013, 59, 173-180

https://doi.org/10.14712/fb2013059050173

Histological Evaluation of the Role of Atypical Antipsychotic Drugs in Inducing Non-Alcoholic Fatty Liver Disease in Adult Male Albino Rats (Light and Electron Microscopic Study)

Hala M. Soliman1,2, H. M. Wagih3,4, S. A. Algaidi1, A. H. Hafiz5

1Department of Anatomy, Faculty of Medicine, Taibah University, Al Madina Al Monawarrah, Kingdom of Saudi Arabia
2Department of Histology and Cell Biology, Faculty of Medicine, Zagazig University, Zagazig, Egypt
3Department of Medical Laboratory Technology, Faculty of Applied Medical Science, Taibah University, Al Madian Al Monawarrah, Kingdom of Saudi Arabia
4Department of Pathology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt
5Psychiatry Hospital, Al Madina Al Monawarrah, Kingdom of Saudi Arabia

Received May 2013
Accepted August 2013

References

1. Albano, E., Mottaran, E., Vidali, M., Reale, E., Saksena, S., Occhino, G., Burt, A. D., Day, C. P. (2005) Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis. Gut 54, 987-993. <https://doi.org/10.1136/gut.2004.057968>
2. Bancroft, J. D., Stevens, A., Turner, D. R. (1996) Theory and Practice of Histological Technique. 4th ed., Churchill Livingston, N.Y., London, San Francisco, Tokyo.
3. Burt, A. D., Mutton, A., Day, C. P. (1998) Diagnosis and interpretation of steatosis and steatohepatitis. Semin. Diagn. Pathol. 15, 246-258.
4. Brunt, E. M., Janney, C. G., Di Bisceglie, A. M, NeuschwanderTetri, B. A, Bacon, B. R. (1999) Non-alcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am. J. Gastroenterol. 94, 2467-2474. <https://doi.org/10.1111/j.1572-0241.1999.01377.x>
5. Brunt, E. M. (2001) Nonalcoholic steatohepatitis: definition and pathology. Semin. Liver. Dis. 21, 3-16. <https://doi.org/10.1055/s-2001-12925>
6. Brunt, E. M., Ramrakhiani, S., Cordes, B. G., NeuschwanderTetri, B. A., Janney, C. G., Bacon, B. R., Di Bisceglie, A. M. (2003) Concurrence of histologic features of steatohepatitis with other forms of chronic liver disease. Mod. Pathol. 16, 49-56. <https://doi.org/10.1097/01.MP.0000042420.21088.C7>
7. Brunt, E. M., Tiniakos, D. G. (2005) Pathological features of NASH. Front. Biosci. 10, 1475-1484.
8. Carleton, H. M. (1980) Histological Technique. Fifth edition, eds. Drury, R. A. B., Wallington, E. A. Oxford University Press, New York.
9. Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER) (2002) Estimating the safe starting dose in clinical trials for therapeutics in adult healthy volunteers. In: Guidance for Industry and Reviewers. U.S. Food and Drug Administration, Rockville, MD.
10. Consumer Health Resource Group, LLC (2009-09-19). “Abilify Side Effects”. www.askapatient.com.http://www.askapatient.com/viewrating.asp?drug=21436&name=ABILIFY. Retrieved 2009; 09-29.
11. Day, C. P., James, O. F. W. (1998) Steatohepatitis: A tale of two ‘hits’? Gastroenterology 114, 842-845. <https://doi.org/10.1016/S0016-5085(98)70599-2>
12. Dean, A. G., Dean, A. J., Coloumbier, D. (1994) Epi-Info. A word processing database and statistics program for epidemiology on microcomputers. Centre for Disease Control and Prevention, Atlanta, GA.
13. Felici, A., Verweij, J., Sparreboom, A. (2002) Dosing strategies for anticancer drugs: the good, the bad and body-surface area. Eur. J. Cancer 38, 1677-1684. <https://doi.org/10.1016/S0959-8049(02)00151-X>
14. Gerbaix, M., Metz, L., Ringot, E., Courteix, D. (2010) Visceral fat mass determination in rodent: validation of dual-energy X-ray absorptiometry and anthropometric techniques in fat and lean rats. Lipids Health Dis. 9, 140. <https://doi.org/10.1186/1476-511X-9-140>
15. Giulio, M., Mara, B., Giampaolo, B., Sara, T., Elisabetta, B., Marco Arthur, J. M., Stefania, N., Gabriele, F., Nazario, M. (2001) Non-alcoholic fatty liver disease. A feature of the metabolic syndrome. Diabetes 50, 1844-1850.
16. Glauret, A. M., Lewis, P. R (1998) Biological specimen preparation for transmission electron microscopy. Embedding methods. In: Practical Methods in Electron Microscopy. Vol. 17. ed. Glauert, A. M., pp 147-169. Portland Press, London.
17. Gupta, R., Rastogi, P., Sarna, M., Gupta, V. P., Sharma, S. K., Kothari, K. (2007) Body-mass index, waist-size, waist-hip ratio and cardiovascular risk factors in urban subjects. J. Assoc. Physicians India 55, 621-627.
18. Haddad, M. P., Wieck, A. (2004) Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 64, 2291-2314. <https://doi.org/10.2165/00003495-200464200-00003>
19. Hasnain, M., Vieweg, W. V. R., Fredrickson, S. K. (2010) Metformin for atypical antipsychotic-induced weight gain and glucose metabolism dysregulation: review of the literature and clinical suggestions. CNS Drugs 24, 193-206. <https://doi.org/10.2165/11530130-000000000-00000>
20. Henderson, D. C., Cagliero, E., Gray, C., Nasrallah, R. A., Hayden, D. L., Schoenfeld, D. A., Goff, D. C. (2000) Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am. J. Psychiatry 157, 975-981. <https://doi.org/10.1176/appi.ajp.157.6.975>
21. Huang, T. L., Chen, J. F. (2005) Serum lipid profiles and schizophrenia: effects of conventional or atypical antipsychotic drugs in Taiwan. Schizophr. Res. 80, 55-59. <https://doi.org/10.1016/j.schres.2005.05.001>
22. Keltner, N. L., Johnson, V. (2002) Biological perspectives. Aripiprazole: a third generation of antipsychotics begins? Perspect. Psychiatr. Care 38, 157-159. <https://doi.org/10.1111/j.1744-6163.2002.tb01566.x>
23. Ludwig, J., McGill, D. B., Lindor, K. D. (1997) Nonalcoholic steatohepatitis. J. Gastroenterol. Hepatol. 12, 398-403. <https://doi.org/10.1111/j.1440-1746.1997.tb00450.x>
24. Meyer, J. M. (2002) A retrospective comparison of weight, lipid, and glucose changes between risperidoneand olanzapine-treated inpatients: metabolic outcomes after 1 year. J. Clin. Psychiatry 63, 425-433. <https://doi.org/10.4088/JCP.v63n0509>
25. Mir, S., Taylor, D. (2001) Atypical antipsychotics and hyperglycaemia. Int. Clin. Psychopharmacol. 16, 63-73. <https://doi.org/10.1097/00004850-200103000-00001>
26. Mortimer, P. A. M. (2007) Review: aripiprazole for schizophrenia – more high quality research required. Evid. Based Ment. Health 10, 14-17.
27. Naomi, A. F., Tim M. G., Thanusha, S. (2007) A review of antipsychotics in the treatment of obsessive compulsive disorder. Focus 5, 354-360.
28. Pousy, D. J., Stigler, K. A., Erickson C. A., McDougle, C. J. (2008) Antipsychotics in the treatment of autism. J. Clin. Invest. 118, 6-14. <https://doi.org/10.1172/JCI32483>
29. Powers, R. E. (2008) Choosing the right neuroleptic for a patient. In: A Short Practical Guide for Psychotropic Medications in Dementia Patients, pp. 7-16, Dementia Education & Training Program for the State of Alabama, Bureau of Geriatric Psychiatry, Tuscaloosa, AL
30. Reynolds, G. P., Zhang, Z. J., Zhang, X. B. (2002) Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet 359, 2086-2087. <https://doi.org/10.1016/S0140-6736(02)08913-4>
31. Rosa, Z. A., Concha, G. A., A. Diana, R,, Federico, V. P., Teresa, B., Luis, T., Vicente, J. M., Juan, R. V. (2005) Inhibition of liver trans-sulphuration pathway by propargylglycine mimics gene expression changes found in the mammary gland of weaned lactating rats: role of glutathione. Biochem. J. 373, 825-834.
32. Shannon, R. S., Minakshi, N., Nihal, A. (2007) Dose translation from animal to human studies revisited. FASEB J. 22, 660-670.
33. Silver, G. A., Gutierrez-Esteinou, R., Mc Quade, R. D. (2007) Aripiprazole – data on efficacy and associated mortality. Br. J. Psychiatry 191, 86-87. <https://doi.org/10.1192/bjp.191.1.86>
34. Stahl, S. M. (2001) Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2: illustrating their mechanism of action. J. Clin. Psychiatry 62, 923-924. <https://doi.org/10.4088/JCP.v62n1201>
35. Swainston, H. T., Perry, C. M. (2004) Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs 64, 1715-1736. <https://doi.org/10.2165/00003495-200464150-00010>
36. Vance, L. A., Jessica, G. J., Pengxiang, S., Charles, H. L., Kevin, P. M., John, L. J., Christopher, J. L. (2011) Olanzapine promotes fat accumulation in male rats by decreasing physical activity, repartitioning energy and increasing adipose tissue lipogenesis while impairing lipolysis. Mol. Psychiatry 16, 569-581.
37. Wahl, R., Ostroff, R. (2005) Reversal of symptomatic hyperprolactinemia by aripiprazole. Am. J. Psychiatry 162, 1542-1543. <https://doi.org/10.1176/appi.ajp.162.8.1542-a>
front cover

ISSN 0015-5500 (Print) ISSN 2533-7602 (Online)

Open access journal

Archive